The deal was agreed for £61 million plus an earn-out of up to £2 million. The company was sold by its founding shareholders, some of whom re-invested in the business. Pearson was also backed by mid-market buy-out specialist ECI Partners.

ECI appointed L.E.K. Consulting to carrying out a commercial due diligence review, which was led by Ken Noonan, head of its European life sciences practice.

“The connectivity of pathology laboratories within hospitals and hospital consortiums, as well as with physicians, is critical to improving the delivery of pathology services across Europe,” Noonan said. “CliniSys is well positioned to be the leader in supporting such connectivity.”